Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 5
2010 10
2011 22
2012 71
2013 99
2014 138
2015 172
2016 191
2017 249
2018 257
2019 266
2020 398
2021 85
Text availability
Article attribute
Article type
Publication date

Search Results

1,707 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib.
Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R. Ajayi S, et al. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. Recent Results Cancer Res. 2018. PMID: 30069628
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2. ...In PV, ruxolitinib effectively controls the hematocrit and reduces splenomegaly. ...
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of Janus kinase (JAK) 1 and JAK2
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitini
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Cao Y, et al. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. J Allergy Clin Immunol. 2020. PMID: 32470486 Free PMC article. Clinical Trial.
Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly …
Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxoliti
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. ...RESULTS: The primary end point was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group …
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. . …
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, Huelsman K, Mokhtari S, Ali H, Malki MMA, Spielberger R, Salhotra A, Zain J, Cotliar J, Parker P, Forman S, Nakamura R. Modi B, et al. Biol Blood Marrow Transplant. 2019 Feb;25(2):265-269. doi: 10.1016/j.bbmt.2018.09.003. Epub 2018 Sep 8. Biol Blood Marrow Transplant. 2019. PMID: 30201397 Free article.
In this retrospective study, we evaluated the outcomes of 46 patients who received ruxolitinib for cGVHD between March 2016 and December 2017 at our institution, and evaluated ruxolitinib's impact at 6 and 12 months, based on the National Institutes of Health Severi …
In this retrospective study, we evaluated the outcomes of 46 patients who received ruxolitinib for cGVHD between March 2016 and Decem …
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Vannucchi AM, et al. N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002. N Engl J Med. 2015. PMID: 25629741 Free PMC article. Clinical Trial.
BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. ...RESULTS: The primary end point was achieved in 21% of the patients in the ruxolitinib group versus 1% of t …
BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia v …
Ruxolitinib for Therapy of Graft-versus-Host Disease.
Neumann T, Schneidewind L, Weigel M, Plis A, Vaizian R, Schmidt CA, Krüger W. Neumann T, et al. Biomed Res Int. 2019 Mar 6;2019:8163780. doi: 10.1155/2019/8163780. eCollection 2019. Biomed Res Int. 2019. PMID: 30956985 Free PMC article.
None of these patients suffered from diarrhea at the initiation of ruxolitinib. CONCLUSION: Ruxolitinib was effective for therapy of acute and chronic GvHD in higher lines in patients without severe diarrhea. Ruxolitinib could replace successfully CNI and hig …
None of these patients suffered from diarrhea at the initiation of ruxolitinib. CONCLUSION: Ruxolitinib was effective for ther …
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B, Biray Avci C. Goker Bagca B, et al. Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20. Cytokine Growth Factor Rev. 2020. PMID: 32636055 Free PMC article. Review.
This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID- …
This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib i …
Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice.
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Bai Y, et al. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. eCollection 2020. Int J Biol Sci. 2020. PMID: 31929748 Free PMC article.
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment displayed less tubular injuries compared with those without Ruxolitinib treatment. ...
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment display
Ruxolitinib: a review of its use in patients with myelofibrosis.
Plosker GL. Plosker GL. Drugs. 2015 Feb;75(3):297-308. doi: 10.1007/s40265-015-0351-8. Drugs. 2015. PMID: 25601187 Review.
Ruxolitinib was also associated with improvements in health-related quality of life and functioning. Despite the crossover of patients in control groups to ruxolitinib, results of the COMFORT studies and their extensions indicate a survival advantage for patients ra
Ruxolitinib was also associated with improvements in health-related quality of life and functioning. Despite the crossover of patient
1,707 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page